^
    1m
    A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Dizal Pharmaceuticals
    New P1 trial
    |
    birelentinib (DZD8586)
    1m
    DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Dizal Pharmaceuticals | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    birelentinib (DZD8586)
    2ms
    DZ2024B0002: A Phase 3 Study of DZD8586 versus Investigators Choice in r/r CLL/SLL (2025-522669-32-00)
    P2/3, N=55, Recruiting, Dizal (Jiangsu) Pharmaceutical Co. Ltd.
    New P2/3 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Zydelig (idelalisib) • bendamustine • Truxima (rituximab-abbs) • birelentinib (DZD8586)
    2ms
    A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) (clinicaltrials.gov)
    P2, N=60, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    birelentinib (DZD8586)
    4ms
    A Phase 2 Study to Evaluate DZD8586 in Adults With ITP (TAI-SHAN11) (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Dizal Pharmaceuticals
    New P2 trial
    |
    birelentinib (DZD8586)
    4ms
    DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Dizal Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 59 | Trial completion date: Apr 2028 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    birelentinib (DZD8586)
    5ms
    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (clinicaltrials.gov)
    P3, N=250, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Zydelig (idelalisib) • bendamustine • birelentinib (DZD8586)
    5ms
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) (clinicaltrials.gov)
    P2, N=66, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • birelentinib (DZD8586)
    7ms
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    New P2 trial
    |
    Venclexta (venetoclax) • birelentinib (DZD8586)
    7ms
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • birelentinib (DZD8586)
    7ms
    A Phase 3 Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (clinicaltrials.gov)
    P3, N=250, Not yet recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Rituxan (rituximab) • Zydelig (idelalisib) • bendamustine • birelentinib (DZD8586)
    9ms
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Dizal Pharmaceuticals
    New P1/2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • birelentinib (DZD8586)